Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

KRRO

Korro Bio Inc.

May 03 • 04:00PM ET

58.24

Dollar change +0.02
Percentage change 0.03	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF DWAS AVSC

Index	-	P/E	-	EPS (ttm)	-63.36	Insider Own	42.35%	Shs Outstand	8.02M	Perf Week	-7.45%
Market Cap	467.08M	Forward P/E	-	EPS next Y	-8.87	Insider Trans	5.48%	Shs Float	4.63M	Perf Month	-18.43%
Income	-81.17M	PEG	-	EPS next Q	-2.38	Inst Own	58.81%	Short Float	2.90%	Perf Quarter	9.17%
Sales	0.00M	P/S	-	EPS this Y	82.75%	Inst Trans	-28.25%	Short Ratio	3.88	Perf Half Y	369.68%
Book/sh	21.20	P/B	2.75	EPS next Y	3.18%	ROA	-47.34%	Short Interest	0.13M	Perf Year	517.93%
Cash/sh	21.16	P/C	2.75	EPS next 5Y	-	ROE	-67.90%	52W Range	4.57 - 97.91	Perf YTD	21.51%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-11.67%	ROI	-40.36%	52W High	-40.52%	Beta	4.02
Dividend TTM	-	Quick Ratio	8.87	Sales past 5Y	-26.84%	Gross Margin	-	52W Low	1173.01%	ATR (14)	5.98
Dividend Ex-Date	-	Current Ratio	8.87	EPS Y/Y TTM	45.55%	Oper. Margin	0.00%	RSI (14)	40.59	Volatility	8.39% 9.45%
Employees	101	Debt/Eq	0.20	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.00	Target Price	130.00
Option/Short	No / Yes	LT Debt/Eq	0.18	EPS Q/Q	80.13%	Payout	-	Rel Volume	0.45	Prev Close	58.22
Sales Surprise	-	EPS Surprise	-42.02%	Sales Q/Q	-	Earnings	Mar 26 AMC	Avg Volume	34.65K	Price	58.24
SMA20	-14.12%	SMA50	-9.56%	SMA200	53.34%	Trades		Volume	15,519	Change	0.03%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-28-24	Reiterated	H.C. Wainwright	Buy	$100 → $115
Feb-27-24	Initiated	BMO Capital Markets	Outperform	$120
Dec-04-23	Initiated	H.C. Wainwright	Buy	$100
Nov-29-23	Initiated	RBC Capital Mkts	Outperform	$70
Nov-10-23	Initiated	Piper Sandler	Overweight	$180
Feb-15-23	Downgrade	Chardan Capital Markets	Buy → Neutral
Feb-13-23	Downgrade	Cowen	Outperform → Market Perform
Sep-22-21	Downgrade	Goldman	Buy → Neutral	$12 → $9
Jan-27-21	Upgrade	JP Morgan	Neutral → Overweight	$56
Dec-22-20	Initiated	B. Riley Securities	Buy	$79
Jul-14-20	Initiated	Oppenheimer	Outperform	$36
May-18-20	Downgrade	JP Morgan	Overweight → Neutral	$27
Oct-28-19	Initiated	JP Morgan	Overweight	$25
Oct-28-19	Initiated	Goldman	Buy	$30
Oct-28-19	Initiated	Cowen	Outperform

Show Previous Ratings

Apr-18-24 08:30AM	Korro Announces $70 Million Private Placement (GlobeNewswire)
Apr-01-24 04:01PM	Korro to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-26-24 04:01PM	Korro Reports Full Year 2023 Financial Results and Highlights Recent Progress (GlobeNewswire) +18.43%
Feb-27-24 09:55AM	Wall Street Analysts Believe Korro Bio, Inc. (KRRO) Could Rally 86.94%: Here's is How to Trade (Zacks) -6.08%
08:00AM	Korro to Present at the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
09:55AM	Loading…
Feb-09-24 09:55AM	Does Korro Bio, Inc. (KRRO) Have the Potential to Rally 59.66% as Wall Street Analysts Expect? (Zacks)
Jan-18-24 08:00AM	Korro Bio Highlights Data for its Lead Program in Alpha-1 Antitrypsin Deficiency (AATD) and Progress Across its RNA Editing Portfolio (GlobeNewswire) -5.98%
Jan-04-24 08:00AM	Korro to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-07-23 08:00AM	Korro Announces Selection of its First Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD) (GlobeNewswire) -14.67%
Nov-28-23 08:00AM	Korro Bio Appoints Dr. Rachel Meyers to Board of Directors (GlobeNewswire) +6.45%
Nov-03-23 03:31PM	UPDATE: Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million (GlobeNewswire) +5.94%
12:19PM	Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million (GlobeNewswire)
Aug-10-23 04:01PM	Frequency Therapeutics Provides Business Updates and Second Quarter 2023 Financial Results (Business Wire)
Jul-17-23 11:59AM	Frequency (FREQ) Up 77% on Merger Deal With Korro Bio (Zacks) -12.66%
Jul-14-23 11:22AM	Why Are Frequency Therapeutics Shares Surging Today (Benzinga) +77.47%
06:30AM	Loading…
06:30AM	Korro Bio and Frequency Therapeutics Announce Merger Agreement (Business Wire)
May-12-23 04:01PM	Frequency Therapeutics Provides Business Updates and First Quarter 2023 Financial Results (Business Wire)
Mar-10-23 07:30AM	Frequency Therapeutics Provides Business Updates and Fourth Quarter and Full Year 2022 Financial Results (Business Wire)
Feb-27-23 07:30AM	Frequency Therapeutics to Participate at Upcoming March Investor Conferences (Business Wire) +5.40%
Feb-13-23 01:55PM	Hearing loss startup to cut more than half of staff in wake of trial failure (American City Business Journals) -80.54%
11:17AM	Frequency Therapeutics' Lead Hearing Loss Program Flunks, Shifts Focus To Multiple Sclerosis, Shares Plunge (Benzinga)
08:05AM	Frequency Therapeutics Announces Topline Results for its Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss (Business Wire)
Dec-19-22 07:30AM	Frequency Therapeutics Announces Formation of Clinical Advisory Board for Remyelination in Multiple Sclerosis Program (Business Wire)
Dec-15-22 07:30AM	Frequency Therapeutics Announces First Patient Dosed in Phase 1b Study of FX-345, the Companys Second Therapeutic Candidate for Sensorineural Hearing Loss (Business Wire)
Nov-17-22 07:30AM	Frequency Therapeutics to Host Virtual Investor Event, Highlighting Hearing Restoration Candidate FX-322 in Advance of Q1 Clinical Results (Business Wire) -10.05%
Nov-08-22 04:05PM	Frequency Therapeutics Provides Business Updates and Third Quarter 2022 Financial Results (Business Wire) -9.51%
Oct-12-22 07:30AM	Frequency Therapeutics Completes Enrollment of Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss (Business Wire) +7.47%
Aug-30-22 07:30AM	Frequency Therapeutics to Participate in September Investor and Medical Conferences (Business Wire)
Aug-09-22 04:05PM	Frequency Therapeutics Provides Business Updates and Second Quarter 2022 Financial Results (Business Wire) -11.11%
Jun-24-22 09:03AM	Frequency Therapeutics (NASDAQ:FREQ) one-year losses have grown faster than shareholder returns have fallen, but the stock jumps 41% this past week (Simply Wall St.) -7.59%
12:00PM	Loading…
May-25-22 12:00PM	Frequency Therapeutics, Inc. (FREQ) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
May-18-22 07:30AM	Frequency Therapeutics to Participate in 2022 H.C. Wainwright Global Investment Conference (Business Wire) -9.02%
May-04-22 04:30PM	Frequency Therapeutics Provides Business Updates and First Quarter 2022 Financial Results (Business Wire)
Apr-22-22 07:30AM	Frequency Therapeutics to Participate in B. Riley Securities Neuro & Ophthalmology Investor Conference (Business Wire)
Apr-08-22 05:00PM	Frequency Exchange Corp. Virtually Closes the Market (PR Newswire) -8.82%
Mar-15-22 07:30AM	Frequency Therapeutics Provides Business Updates and Reports Fourth Quarter and Full Year 2021 Financial Results (Business Wire) +15.29%
Mar-10-22 06:35PM	Poseida Therapeutics, Inc. (PSTX) Beats Q4 Earnings and Revenue Estimates (Zacks) -13.70%
Feb-28-22 07:30AM	Frequency Therapeutics to Participate in Upcoming March 2022 Investor Conferences (Business Wire)
Jan-14-22 05:43AM	One Frequency Therapeutics, Inc. (NASDAQ:FREQ) insider upped their stake in the previous year (Simply Wall St.)
Jan-04-22 07:30AM	Frequency Therapeutics to Present 2022 Business and Pipeline Overview at the 40th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-28-21 02:38AM	Destra Investment Trust Buys ThredUp Inc, Etsy Inc, Riskified, Sells , , 2U Inc (GuruFocus.com) +5.28%
Dec-09-21 01:18PM	Frequency Therapeutics' Hearing Loss Candidate Shows Improved Speech Perception In Noise (Benzinga)
07:30AM	Frequency Therapeutics Shares Results from FX-322-113 Severe Sensorineural Hearing Loss Study Showing Speech Perception Improvements in Noise (Business Wire)
Nov-30-21 05:53AM	Frequency Therapeutics (NASDAQ:FREQ) investors are sitting on a loss of 81% if they invested a year ago (Simply Wall St.)
Nov-15-21 12:25PM	Frequency Therapeutics, Inc. (FREQ) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:30AM	Frequency Therapeutics Provides Business Updates and Third Quarter 2021 Financial Results (Business Wire)
Nov-09-21 07:30AM	Frequency Therapeutics Holds Virtual R&D Event Highlighting Clinical Advancement of FX-322, a New Potential Restorative Treatment for Hearing Loss and In Vivo Data for Its Remyelination Program in Multiple Sclerosis (Business Wire)
Nov-08-21 03:00PM	Analysts Estimate Frequency Therapeutics, Inc. (FREQ) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-27-21 07:30AM	Frequency Therapeutics Virtual R&D Event to Detail FX-322 Clinical Advances, a New Program for Hearing Restoration and In Vivo Data from its MS Remyelination Program (Business Wire)
Oct-21-21 07:30AM	Frequency Therapeutics Announces First Subject Dosed in FX-322 Phase 2b Acquired Sensorineural Hearing Loss (SNHL) Study and FDA Agreement on Speech Perception as Primary Endpoint (Business Wire)
Oct-01-21 08:23AM	Do Insiders Own Lots Of Shares In Frequency Therapeutics, Inc. (NASDAQ:FREQ)? (Simply Wall St.)
Sep-22-21 11:18AM	Frequency Therapeutics' New Data Of Hearing Loss Candidate Fails To Impress Investors (Benzinga)
07:30AM	Frequency Therapeutics Announces New FX-322 Results Showing That Additional Study Participants Gain Hearing Improvements at Later Time Points (Business Wire)
Sep-08-21 07:30AM	Frequency Therapeutics to Present at Upcoming Investor Conferences (Business Wire)
Aug-30-21 05:10PM	Lifshitz Law Firm, P.C. Announces Investigations of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), Frequency Therapeutics, Inc. (NasdaqGS: FREQ), RLX Technology Inc. (NYSE: RLX), and Washington Prime Group, Inc. (NYSE: WPG) (ACCESSWIRE)
Aug-12-21 04:06PM	Moore Kuehn, PLLC Encourages Investors of FREQ to Contact Law Firm (Newsfile)
08:45AM	Frequency Therapeutics, Inc. (FREQ) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Frequency Therapeutics Provides Business Updates and Second Quarter 2021 Financial Results (Business Wire)
Aug-04-21 03:00PM	Analysts Estimate Frequency Therapeutics, Inc. (FREQ) to Report a Decline in Earnings: What to Look Out for (Zacks)
Aug-02-21 03:05PM	CLASS ACTION UPDATE for JRVR, FREQ and QFIN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders (ACCESSWIRE)
02:30PM	Final Deadline Alert: Frequency Therapeutics, Inc. (FREQ) Class Action and Last Chance for Investors to Actively Participate - Bronstein, Gewirtz & Grossman, LLC (ACCESSWIRE)
12:30PM	SHAREHOLDER ALERT: FREQ RKT QFIN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines (ACCESSWIRE)
12:30PM	FINAL DEADLINE ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Frequency Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm (ACCESSWIRE)
11:00AM	FREQ Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Frequency Therapeutics, Inc. (FREQ) Shareholders of Class Action and Lead Plaintiff Deadline: August 2, 2021 (ACCESSWIRE)
10:00AM	The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of FREQ, RKT and BZ (ACCESSWIRE)
09:16AM	FREQ Final Deadline Today: Rosen, National Trial Lawyers, Encourages Frequency Therapeutics, Inc. Investors to Secure Counsel Before Important August 2 Deadline in Securities Class Action - FREQ (Newsfile)
09:09AM	DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Frequency Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm (Newsfile)
05:50AM	The Gross Law Firm Announces Class Actions on Behalf of Shareholders of FREQ, RLX and DIDI (ACCESSWIRE)
03:27AM	Frequency Therapeutics (NASDAQ:FREQ) Has Debt But No Earnings; Should You Worry? (Simply Wall St.)
Aug-01-21 10:38AM	FREQUENCY DEADLINE ALERT: Faruqi & Faruqi LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Frequency To Contact Him Directly To Discuss Their Options (GlobeNewswire)
06:36AM	FREQ FINAL DEADLINE: ROSEN, A TOP RANKED FIRM, Encourages Frequency Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline Tomorrow in Securities Class Action - FREQ (Newsfile)
Jul-30-21 08:49PM	DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Frequency Therapeutics, Inc. and Encourages Investors to Contact the Firm (Business Wire)
07:19PM	Frequency Therapeutics, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm (GlobeNewswire)
07:10PM	SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Frequency Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - FREQ (ACCESSWIRE)
05:15PM	FREQ Final Deadline Monday: Rosen, Leading Trial Attorneys, Encourages Frequency Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important August 2 Deadline in Securities Class Action - FREQ (Newsfile)
02:57PM	FREQ LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Frequency Therapeutics, Inc. (Newsfile)
01:30PM	FINAL DEADLINE IMMINENT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Frequency Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm (ACCESSWIRE)
12:40PM	The Gross Law Firm Announces Class Actions on Behalf of Shareholders of FREQ, OCGN and BLCT (ACCESSWIRE)
11:30AM	The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Frequency Therapeutics, Inc. (FREQ) (Business Wire)
11:30AM	CLASS ACTION UPDATE for CCIV, FREQ and RLX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders (ACCESSWIRE)
11:00AM	FREQ INVESTOR ALERT: Shareholder Lawsuit Deadline Approaching (ACCESSWIRE)
10:00AM	SHAREHOLDER ALERT: FREQ RLX DIDI: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines (ACCESSWIRE)
10:00AM	FREQ Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Frequency Therapeutics, Inc. (FREQ) Shareholders of Class Action and Lead Plaintiff Deadline: August 2, 2021 (GlobeNewswire)
09:30AM	MONDAY DEADLINE NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Frequency Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm (Newsfile)
09:00AM	FREQUENCY THERAPEUTICS SHAREHOLDERS: August 2, 2021 Filing Deadline in Class Action - Contact Lieff Cabraser (ACCESSWIRE)
05:18AM	FREQ ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of August 2, 2021 in the Class Action Filed on Behalf of Frequency Therapeutics, Inc. Limited Shareholders (Newsfile)
Jul-29-21 08:47PM	Frequency Class Action Reminder (Newsfile)
05:29PM	SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Frequency Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 2, 2021 - FREQ (Newsfile)
04:02PM	MONDAY DEADLINE: Investors with Substantial Losses Have Opportunity to Lead the Frequency Therapeutics, Inc. Class Action Lawsuit - FREQ (PR Newswire)
01:15PM	The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of FREQ, RLX and OTLY (ACCESSWIRE)
12:30PM	FREQ DEADLINE ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Frequency Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Monday Deadline in Securities Class Action FREQ (GlobeNewswire)
10:45AM	Lawsuits Filed Against FREQ, DIDI and OTLY - Jakubowitz Law Pursues Shareholders Claims (ACCESSWIRE)
10:00AM	FREQ Monday Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Frequency Therapeutics, Inc. (FREQ) Shareholders of Class Action and Lead Plaintiff Deadline: August 2, 2021 (ACCESSWIRE)
09:24AM	MONDAY DEADLINE REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Frequency Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm (Newsfile)
05:27AM	SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Frequency Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 2, 2021 - (FREQ) (Newsfile)
Jul-28-21 08:00PM	Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Frequency, Athira, Full Truck, and Coinbase and Encourages Investors to Contact the Firm (GlobeNewswire)
07:25PM	SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Frequency Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - FREQ (PR Newswire)
07:07PM	FREQ LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Frequency Therapeutics, Inc. (Newsfile)
05:34PM	Frequency Shareholder Notice (Newsfile)
03:16PM	FREQ ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of August 2, 2021 in the Class Action Filed on Behalf of Frequency Therapeutics, Inc. Limited Shareholders (Newsfile)

Korro Bio, Inc. is an RNA editing company, which engages in the discovery and development of genetic medicines. The company was founded by Nessan Bermingham, Jean-Francois Formela, Joshua Rosenthal, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Mathers Edward T	10% Owner	Apr 22 '24	Buy	56.00	17,857	999,992	1,090,793	Apr 24 05:00 PM
SANDELL SCOTT D	10% Owner	Apr 22 '24	Buy	56.00	17,857	999,992	1,090,793	Apr 24 05:00 PM
Makhzoumi Mohamad	10% Owner	Apr 22 '24	Buy	56.00	17,857	999,992	1,090,793	Apr 24 05:00 PM
Yang Rick	10% Owner	Apr 22 '24	Buy	56.00	17,857	999,992	1,090,793	Apr 24 05:00 PM
Walker Paul Edward	10% Owner	Apr 22 '24	Buy	56.00	17,857	999,992	1,090,793	Apr 24 05:00 PM
Florence Anthony A. Jr.	10% Owner	Apr 22 '24	Buy	56.00	17,857	999,992	1,090,793	Apr 24 05:00 PM
Chang Carmen	10% Owner	Apr 22 '24	Buy	56.00	17,857	999,992	1,090,793	Apr 24 05:00 PM
BASKETT FOREST	10% Owner	Apr 22 '24	Buy	56.00	17,857	999,992	1,090,793	Apr 24 05:00 PM
New Enterprise Associates 17,	10% Owner	Apr 22 '24	Buy	56.00	17,857	999,992	1,090,793	Apr 24 05:00 PM
Atlas Venture Opportunity Fund	10% Owner	Apr 22 '24	Buy	56.00	17,857	999,992	195,074	Apr 23 05:23 PM
Lucchino David L.	Director	Nov 22 '23	Sale	37.69	1,156	43,573	22,150	Nov 27 08:48 PM
Lucchino David L.	Director	Nov 10 '23	Sale	41.97	968	40,632	23,306	Nov 22 04:05 PM
Lucchino David L.	President and CEO	Aug 18 '23	Sale	0.60	2,865	1,719	636,801	Aug 22 04:19 PM
Mitrano Richard J.	VP Finance & Operations	Aug 18 '23	Sale	0.63	227	143	48,694	Aug 22 04:21 PM
Lucchino David L.	President and CEO	Aug 17 '23	Sale	0.63	2,733	1,722	639,666	Aug 18 08:01 AM
Mitrano Richard J.	VP Finance & Operations	Aug 17 '23	Sale	0.62	230	143	48,921	Aug 18 08:05 AM
Lucchino David L.	President and CEO	Aug 16 '23	Sale	0.65	2,895	1,882	642,399	Aug 18 08:01 AM
Mitrano Richard J.	VP Finance & Operations	Aug 16 '23	Sale	0.67	234	157	49,151	Aug 18 08:05 AM
Lucchino David L.	President and CEO	Aug 15 '23	Sale	0.67	2,629	1,761	645,294	Aug 16 08:59 AM
Mitrano Richard J.	VP Finance & Operations	Aug 15 '23	Sale	0.65	228	148	49,385	Aug 16 09:02 AM
Lucchino David L.	President and CEO	Aug 14 '23	Sale	0.63	2,881	1,815	647,923	Aug 16 08:59 AM
Mitrano Richard J.	VP Finance & Operations	Aug 14 '23	Sale	0.64	238	152	49,613	Aug 16 09:02 AM
Lucchino David L.	President and CEO	Aug 11 '23	Sale	0.67	2,733	1,831	650,804	Aug 14 04:07 PM
Mitrano Richard J.	VP Finance & Operations	Aug 11 '23	Sale	0.64	240	154	49,851	Aug 14 04:06 PM
Lucchino David L.	President and CEO	Aug 10 '23	Sale	0.68	2,790	1,897	653,537	Aug 14 04:07 PM
Mitrano Richard J.	VP Finance & Operations	Aug 10 '23	Sale	0.64	247	158	50,091	Aug 14 04:06 PM
Lucchino David L.	President and CEO	Aug 09 '23	Sale	0.67	2,798	1,875	656,327	Aug 10 04:04 PM
Mitrano Richard J.	VP Finance & Operations	Aug 09 '23	Sale	0.66	238	157	50,338	Aug 10 04:02 PM
Lucchino David L.	President and CEO	Aug 08 '23	Sale	0.69	2,810	1,939	659,125	Aug 10 04:04 PM
Mitrano Richard J.	VP Finance & Operations	Aug 08 '23	Sale	0.67	241	161	50,576	Aug 10 04:02 PM
Lucchino David L.	President and CEO	Aug 07 '23	Sale	0.68	2,857	1,943	661,935	Aug 09 08:51 AM
Mitrano Richard J.	VP Finance & Operations	Aug 07 '23	Sale	0.69	235	162	50,817	Aug 09 08:50 AM
Lucchino David L.	President and CEO	Aug 04 '23	Sale	0.69	2,550	1,759	664,792	Aug 09 08:51 AM
Mitrano Richard J.	VP Finance & Operations	Aug 04 '23	Sale	0.67	220	147	51,052	Aug 09 08:50 AM
Lucchino David L.	President and CEO	Aug 03 '23	Sale	0.59	2,679	1,581	667,342	Aug 04 04:10 PM
Mitrano Richard J.	VP Finance & Operations	Aug 03 '23	Sale	0.56	232	130	51,272	Aug 04 04:09 PM
Lucchino David L.	President and CEO	Aug 02 '23	Sale	0.52	2,587	1,345	670,021	Aug 04 04:10 PM
Mitrano Richard J.	VP Finance & Operations	Aug 02 '23	Sale	0.49	231	113	51,504	Aug 04 04:09 PM
Lucchino David L.	President and CEO	Aug 01 '23	Sale	0.49	2,799	1,372	672,608	Aug 02 04:36 PM
Mitrano Richard J.	VP Finance & Operations	Aug 01 '23	Sale	0.48	238	114	51,735	Aug 02 04:35 PM
Lucchino David L.	President and CEO	Jul 31 '23	Sale	0.50	2,676	1,338	675,407	Aug 02 04:36 PM
Mitrano Richard J.	VP Finance & Operations	Jul 31 '23	Sale	0.50	222	111	51,973	Aug 02 04:35 PM
Lucchino David L.	President and CEO	Jul 28 '23	Sale	0.47	2,647	1,244	678,083	Jul 31 04:05 PM
Loose Christopher R.	Chief Scientific Officer	Jul 28 '23	Sale	0.46	1,344	618	183,650	Jul 31 04:01 PM
Mitrano Richard J.	VP Finance & Operations	Jul 28 '23	Sale	0.47	223	105	52,195	Jul 31 04:09 PM
Lucchino David L.	President and CEO	Jul 27 '23	Sale	0.51	2,791	1,423	680,730	Jul 31 04:05 PM
Loose Christopher R.	Chief Scientific Officer	Jul 27 '23	Sale	0.53	1,373	728	184,994	Jul 31 04:01 PM
Mitrano Richard J.	VP Finance & Operations	Jul 27 '23	Sale	0.53	227	120	52,418	Jul 31 04:09 PM
Lucchino David L.	President and CEO	Jul 26 '23	Sale	0.52	2,609	1,357	683,521	Jul 27 04:15 PM
Loose Christopher R.	Chief Scientific Officer	Jul 26 '23	Sale	0.51	1,329	678	186,367	Jul 27 04:16 PM
Mitrano Richard J.	VP Finance & Operations	Jul 26 '23	Sale	0.53	222	118	52,645	Jul 27 04:16 PM
Lucchino David L.	President and CEO	Jul 25 '23	Sale	0.50	2,803	1,402	686,130	Jul 27 04:15 PM
Loose Christopher R.	Chief Scientific Officer	Jul 25 '23	Sale	0.50	1,390	695	187,696	Jul 27 04:16 PM
Mitrano Richard J.	VP Finance & Operations	Jul 25 '23	Sale	0.50	234	117	52,867	Jul 27 04:16 PM
Lucchino David L.	President and CEO	Jul 24 '23	Sale	0.54	2,887	1,559	688,933	Jul 25 04:56 PM
Loose Christopher R.	Chief Scientific Officer	Jul 24 '23	Sale	0.54	1,438	777	189,086	Jul 25 04:56 PM
Mitrano Richard J.	VP Finance & Operations	Jul 24 '23	Sale	0.56	234	131	53,101	Jul 25 04:55 PM
Lucchino David L.	President and CEO	Jul 21 '23	Sale	0.61	2,663	1,624	691,820	Jul 25 04:56 PM
Loose Christopher R.	Chief Scientific Officer	Jul 21 '23	Sale	0.61	1,333	813	190,524	Jul 25 04:56 PM
Mitrano Richard J.	VP Finance & Operations	Jul 21 '23	Sale	0.61	223	136	53,335	Jul 25 04:55 PM
Lucchino David L.	President and CEO	Jul 20 '23	Sale	0.64	2,710	1,734	694,483	Jul 21 04:06 PM
Loose Christopher R.	Chief Scientific Officer	Jul 20 '23	Sale	0.64	1,361	871	191,857	Jul 21 04:07 PM
Mitrano Richard J.	VP Finance & Operations	Jul 20 '23	Sale	0.64	229	147	53,558	Jul 21 04:04 PM
Lucchino David L.	President and CEO	Jul 19 '23	Sale	0.65	2,646	1,720	697,193	Jul 21 04:06 PM
Loose Christopher R.	Chief Scientific Officer	Jul 19 '23	Sale	0.65	1,335	868	193,218	Jul 21 04:07 PM
Mitrano Richard J.	VP Finance & Operations	Jul 19 '23	Sale	0.63	228	144	53,787	Jul 21 04:04 PM
Lucchino David L.	President and CEO	Jul 18 '23	Sale	0.56	2,968	1,662	699,839	Jul 19 04:14 PM
Loose Christopher R.	Chief Scientific Officer	Jul 18 '23	Sale	0.56	1,484	831	194,553	Jul 19 04:13 PM
Mitrano Richard J.	VP Finance & Operations	Jul 18 '23	Sale	0.56	249	139	54,015	Jul 19 04:16 PM
Lucchino David L.	President and CEO	Jul 17 '23	Sale	0.68	2,775	1,887	702,807	Jul 19 04:14 PM
Loose Christopher R.	Chief Scientific Officer	Jul 17 '23	Sale	0.67	1,415	948	196,037	Jul 19 04:13 PM
Mitrano Richard J.	VP Finance & Operations	Jul 17 '23	Sale	0.65	244	159	54,264	Jul 19 04:16 PM
Lucchino David L.	President and CEO	Jul 14 '23	Sale	0.59	1,815	1,071	705,582	Jul 17 04:22 PM
Loose Christopher R.	Chief Scientific Officer	Jul 14 '23	Sale	0.59	906	535	197,452	Jul 17 04:23 PM
Mitrano Richard J.	VP Finance & Operations	Jul 14 '23	Sale	0.60	148	89	54,508	Jul 17 04:20 PM
Lucchino David L.	President and CEO	Jul 13 '23	Sale	0.39	2,646	1,032	707,397	Jul 17 04:22 PM
Loose Christopher R.	Chief Scientific Officer	Jul 13 '23	Sale	0.39	1,329	518	198,358	Jul 17 04:23 PM
Mitrano Richard J.	VP Finance & Operations	Jul 13 '23	Sale	0.39	227	89	54,656	Jul 17 04:20 PM
Lucchino David L.	President and CEO	Jul 12 '23	Sale	0.39	2,649	1,033	710,043	Jul 13 04:14 PM
Loose Christopher R.	Chief Scientific Officer	Jul 12 '23	Sale	0.39	1,335	521	199,687	Jul 13 04:42 PM
Mitrano Richard J.	VP Finance & Operations	Jul 12 '23	Sale	0.40	220	88	54,883	Jul 13 04:09 PM
Lucchino David L.	President and CEO	Jul 11 '23	Sale	0.37	2,731	1,010	712,692	Jul 13 04:14 PM
Loose Christopher R.	Chief Scientific Officer	Jul 11 '23	Sale	0.37	1,363	504	201,022	Jul 13 04:42 PM
Mitrano Richard J.	VP Finance & Operations	Jul 11 '23	Sale	0.37	228	84	55,103	Jul 13 04:09 PM
Lucchino David L.	President and CEO	Jul 10 '23	Sale	0.38	2,591	985	442,696	Jul 11 05:24 PM
Loose Christopher R.	Chief Scientific Officer	Jul 10 '23	Sale	0.37	1,304	482	66,023	Jul 11 05:35 PM
Mitrano Richard J.	VP Finance & Operations	Jul 10 '23	Sale	0.37	220	81	32,605	Jul 11 05:29 PM
Lucchino David L.	President and CEO	Jul 07 '23	Sale	0.35	2,634	922	436,196	Jul 11 05:24 PM
Loose Christopher R.	Chief Scientific Officer	Jul 07 '23	Sale	0.36	1,306	470	62,781	Jul 11 05:35 PM
Mitrano Richard J.	VP Finance & Operations	Jul 07 '23	Sale	0.36	220	79	32,067	Jul 11 05:29 PM
Lucchino David L.	President and CEO	Jul 06 '23	Sale	0.34	2,773	943	429,739	Jul 07 04:56 PM
Loose Christopher R.	Chief Scientific Officer	Jul 06 '23	Sale	0.34	1,384	471	57,758	Jul 07 04:54 PM
Mitrano Richard J.	VP Finance & Operations	Jul 06 '23	Sale	0.35	224	78	31,529	Jul 07 05:06 PM

Open in Screener

NTLA

Intellia Therapeutics Inc

May 03 • 04:00PM ET

23.60

Dollar change +0.33
Percentage change 1.42	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

NTLA Intellia Therapeutics Inc daily Stock Chart

Held by: ARKK VTI VB ARKG IWM VXF VBK IWN IBB XT

Index	RUT	P/E	-	EPS (ttm)	-5.42	Insider Own	2.33%	Shs Outstand	96.44M	Perf Week	13.68%
Market Cap	2.28B	Forward P/E	-	EPS next Y	-5.64	Insider Trans	-2.32%	Shs Float	94.19M	Perf Month	-5.49%
Income	-481.19M	PEG	-	EPS next Q	-1.37	Inst Own	85.14%	Short Float	15.49%	Perf Quarter	-6.68%
Sales	36.27M	P/S	62.75	EPS this Y	-1.29%	Inst Trans	-0.30%	Short Ratio	9.85	Perf Half Y	-7.45%
Book/sh	11.29	P/B	2.09	EPS next Y	-2.69%	ROA	-34.11%	Short Interest	14.59M	Perf Year	-38.83%
Cash/sh	9.46	P/C	2.49	EPS next 5Y	30.00%	ROE	-42.10%	52W Range	19.37 - 47.48	Perf YTD	-22.60%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-22.30%	ROI	-41.96%	52W High	-50.29%	Beta	1.85
Dividend TTM	-	Quick Ratio	8.67	Sales past 5Y	12.09%	Gross Margin	75.26%	52W Low	21.84%	ATR (14)	1.32
Dividend Ex-Date	-	Current Ratio	8.67	EPS Y/Y TTM	12.31%	Oper. Margin	-1420.51%	RSI (14)	50.91	Volatility	6.24% 5.03%
Employees	526	Debt/Eq	0.11	Sales Y/Y TTM	-30.40%	Profit Margin	-1326.51%	Recom	1.54	Target Price	69.57
Option/Short	Yes / Yes	LT Debt/Eq	0.09	EPS Q/Q	-4.64%	Payout	-	Rel Volume	0.87	Prev Close	23.27
Sales Surprise	-115.04%	EPS Surprise	-1.49%	Sales Q/Q	-114.12%	Earnings	May 09 BMO	Avg Volume	1.48M	Price	23.60
SMA20	3.97%	SMA50	-9.59%	SMA200	-21.80%	Trades		Volume	1,294,381	Change	1.42%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-23-24	Downgrade	Goldman	Buy → Neutral	$136 → $32
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Apr-13-23	Initiated	Canaccord Genuity	Buy	$66
Mar-21-23	Initiated	Bernstein	Outperform	$54
Mar-14-23	Upgrade	BMO Capital Markets	Market Perform → Outperform	$54 → $57
Feb-01-23	Initiated	Cantor Fitzgerald	Overweight	$67
Jan-24-23	Upgrade	Citigroup	Sell → Neutral	$48 → $39
Jan-19-23	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Oct-11-22	Initiated	Morgan Stanley	Overweight	$84
Sep-21-22	Initiated	JP Morgan	Overweight	$85
Sep-01-22	Initiated	Citigroup	Sell	$50
Jun-17-22	Initiated	BMO Capital Markets	Market Perform	$54
Jun-16-22	Initiated	BofA Securities	Buy	$70
Apr-28-22	Initiated	Credit Suisse	Outperform	$100
Feb-18-22	Initiated	William Blair	Outperform	$144
Feb-07-22	Upgrade	Oppenheimer	Perform → Outperform	$145 → $150
Jan-31-22	Initiated	Cowen	Outperform
Jan-07-22	Initiated	Piper Sandler	Overweight	$171
Oct-05-21	Initiated	Guggenheim	Buy	$170
Sep-24-21	Initiated	Stifel	Buy	$173

Show Previous Ratings

May-03-24 06:15PM	Why Intellia Therapeutics, Inc. (NTLA) Outpaced the Stock Market Today (Zacks)
02:18PM	Shhh! 3 Secret Gene Editing Stocks Flying Below Wall Street's Radar (InvestorPlace)
May-02-24 07:30AM	Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company Updates (GlobeNewswire)
06:04AM	3 Gene Editing Stocks with the Potential to Make You an Overnight Millionaire (InvestorPlace)
Apr-29-24 07:30AM	Intellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024 (GlobeNewswire) +5.88%
11:21AM	Loading…
Apr-25-24 11:21AM	Intellia (NTLA) to Report Q1 Earnings: What's in the Cards? (Zacks) -5.43%
10:01AM	Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q1 Earnings Expected to Decline (Zacks)
Apr-14-24 05:55AM	2 Stocks Down 30% to Buy Right Now (Motley Fool)
Apr-12-24 04:50AM	Cathie Wood Goes Bargain Hunting. 2 Stocks She Bought This Week. (Motley Fool)
Apr-09-24 04:50AM	Bull Market and Beyond: 3 Stocks Just Waiting to Soar (Motley Fool)
Mar-28-24 05:55AM	Better Cathie Wood Stock: Moderna vs. Intellia (Motley Fool)
Mar-21-24 05:29PM	Hot Stocks: The 3 Best Opportunities for Investing in Biotech (InvestorPlace)
04:19PM	3 Stocks That Could Be the Next Big Thing in Gene Editing (InvestorPlace)
Mar-19-24 01:06PM	Intellia (NTLA) Begins Dosing in Phase III ATTR Amyloidosis Study (Zacks)
Mar-18-24 07:30AM	Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy (GlobeNewswire)
09:45AM	Loading…
Mar-09-24 09:45AM	Is Intellia Therapeutics Stock a Buy Now? (Motley Fool)
Mar-06-24 10:35AM	Intellia Therapeutics Stock Has 119% Upside, According to 1 Wall Street Analyst (Motley Fool)
Mar-01-24 01:43PM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research)
Feb-29-24 05:50AM	A Bull Market Is Here: 2 Magnificent Stocks Down 80% to Buy Right Now (Motley Fool)
Feb-28-24 09:30AM	Intellia Therapeutics, Inc. (NTLA) Crossed Above the 50-Day Moving Average: What That Means for Investors (Zacks) +5.74%
Feb-27-24 11:55AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (Motley Fool) +12.15%
09:35AM	Intellia Therapeutics, Inc. (NTLA) Just Overtook the 20-Day Moving Average (Zacks)
Feb-23-24 12:22PM	Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q4 2023 Earnings Call Transcript (Insider Monkey)
11:12AM	Intellia (NTLA) Beats on Q4 Earnings, Provides Pipeline Update (Zacks)
09:55AM	Wall Street Analysts See an 185.54% Upside in Intellia Therapeutics, Inc. (NTLA): Can the Stock Really Move This High? (Zacks)
Feb-22-24 10:53PM	Q4 2023 Intellia Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
08:12AM	Intellia Therapeutics Inc (NTLA) Reports Full-Year 2023 Financial Results and Operational Progress (GuruFocus.com)
07:30AM	Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
Feb-20-24 05:02AM	Cathie Wood Is Betting on This Top Technology: 2 Stocks She Just Bought (Motley Fool)
Feb-17-24 01:59AM	Analysts Say Intellia Therapeutics Stock Could Rise 157% This Year, but Will It Happen? (Motley Fool)
10:00AM	Loading…
Feb-15-24 10:00AM	Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks)
07:30AM	Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis (GlobeNewswire)
06:20AM	Intellia, ReCode partner on genetic medicines for cystic fibrosis (BioPharma Dive)
Feb-14-24 07:30AM	Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2023 Earnings and Company Updates (GlobeNewswire) +6.92%
Feb-13-24 06:05AM	3 Gene Editing Stocks With Unprecedented Surge Potential (InvestorPlace) -10.67%
Feb-10-24 05:09PM	Top 11 CRISPR Stocks To Invest In (Insider Monkey)
Feb-08-24 01:15PM	The 3 Most Undervalued Biotech Stocks to Buy in February 2024 (InvestorPlace) +5.37%
Feb-07-24 11:50AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (Motley Fool)
Feb-05-24 05:25AM	A Bull Market Is Here: 2 Top Growth Stocks to Buy Hand Over Fist (Motley Fool)
Jan-31-24 05:00PM	Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine (GlobeNewswire)
12:28PM	3 Once-in-a-Lifetime Gene Editing Stocks with Unprecedented Surge Potential (InvestorPlace)
Jan-30-24 05:10AM	History Says the S&P 500 May Climb in the Triple Digits During This Bull Market. 3 Top Growth Stocks to Buy Before it Does. (Motley Fool) -6.07%
Jan-29-24 09:35AM	Down -19.06% in 4 Weeks, Here's Why Intellia Therapeutics, Inc. (NTLA) Looks Ripe for a Turnaround (Zacks) +6.08%
Jan-27-24 01:25PM	2 Growth Stocks That Could Rocket 144% and 202% Higher This Year, According to Wall Street (Motley Fool)
08:55AM	Is It Too Late to Buy Intellia Therapeutics Stock? (Motley Fool)
Jan-24-24 07:00AM	SparingVision Reaches Final Dose Escalation Step in PRODYGY Trial with SPVN06 for retinitis pigmentosa (GlobeNewswire)
Jan-22-24 05:41PM	3 Biotech Stocks to Turn $10,000 Into $1 Million: January 2024 (InvestorPlace)
Jan-21-24 08:00AM	Better Growth Stock: Intellia Therapeutics vs. CRISPR Therapeutics (Motley Fool)
Jan-18-24 11:50AM	Is it a Good Idea to Invest in Intellia (NTLA) Stock Now? (Zacks)
Jan-13-24 06:05AM	The Top Healthcare Stocks to Buy With $100 (Motley Fool)
Jan-12-24 08:44AM	Is Intellia Therapeutics (NTLA) Stock a Solid Choice Right Now? (Zacks)
Jan-08-24 07:45AM	Better Gene-Editing Stock: Editas Medicine vs. Intellia Therapeutics (Motley Fool) +5.03%
05:52AM	4 Cathie Wood Stocks Wall Street Thinks Will Skyrocket 83% to 168% in 2024 (Motley Fool)
Jan-05-24 10:04AM	Intellia Therapeutics Layoffs 2024: What to Know About the Latest NTLA Job Cuts (InvestorPlace)
Jan-04-24 04:01PM	Intellia Therapeutics Highlights its Three-Year Strategic Priorities and Anticipated 2024 Key Milestones (GlobeNewswire)
12:47PM	Intellia to lay off staff, cut some early research (BioPharma Dive)
Dec-31-23 08:45AM	2 Gene-Editing Stocks That Might Be the Next CRISPR Therapeutics (Motley Fool)
Dec-27-23 06:41PM	13 Most Promising Future Stocks To Buy According To Hedge Funds (Insider Monkey)
Dec-16-23 05:00AM	5 Beaten-Down Stocks That Could Soar in 2024 (Motley Fool)
Dec-13-23 05:20AM	3 Gene-Editing Stocks With the Potential to Mint Millionaires (InvestorPlace) +7.96%
Dec-12-23 06:00AM	Could Intellia Therapeutics Become the Next CRISPR Therapeutics? (Motley Fool)
Dec-10-23 11:57AM	5 Best Genomics Stocks To Buy Now (Insider Monkey)
Nov-28-23 05:30AM	2 Dirt-Cheap Stocks That Could Rocket Higher in a Bull Market (Motley Fool)
Nov-24-23 07:00AM	Gene Editing Will Change Medicineand Maybe Health Investing Too (The Wall Street Journal)
Nov-15-23 11:07AM	Intellia (NTLA) Rises on EC's Orphan Drug Tag for HAE Candidate (Zacks)
Nov-14-23 07:30AM	Intellia Therapeutics Receives European Union Orphan Drug Designation for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema (GlobeNewswire) +11.09%
Nov-10-23 05:38PM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research)
06:30AM	Intellia (NTLA) Beats on Q3 Earnings, Provides Pipeline Update (Zacks)
Nov-09-23 04:06PM	Market Today: Tech Stocks Under Pressure Amid Mixed Earnings and Fed Remarks (GuruFocus.com) -12.27%
03:37PM	3 Biotech Stocks That Are Betting on the Future of Gene Editing (InvestorPlace)
08:29AM	Intellia Therapeutics Inc (NTLA) Reports Q3 2023 Financial Results and Progress in CRISPR Therapies (GuruFocus.com)
07:30AM	Intellia Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
Nov-06-23 08:02AM	Cathie Wood's ARK Innovation Just Had Its Best Week Ever Thanks To Roku, These Huge Winners (Investor's Business Daily)
Nov-02-23 07:00AM	Intellia Presents New Interim Data from the Ongoing Phase 1 Study of NTLA-2001 at the 4th International ATTR Amyloidosis Meeting (GlobeNewswire)
06:45AM	1 Supercharged Growth Stock That Could Make You a Millionaire in 10 Years (Motley Fool)
Oct-30-23 03:46PM	Top 20 Genomics Companies in the World (Insider Monkey)
10:00AM	Beam Therapeutics Inc. (BEAM) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Oct-28-23 07:30AM	Intellia Therapeutics Will Soon Make Biotech History. Is the Stock a Buy? (Motley Fool)
Oct-26-23 10:02AM	Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
07:30AM	Intellia Therapeutics to Present Updated Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis and Hold Conference Call to Discuss Third Quarter 2023 Earnings in November (GlobeNewswire)
Oct-23-23 09:40AM	Intellia (NTLA) Focuses on Developing Gene-Editing Therapies (Zacks)
08:45AM	3 Stocks Cathie Wood Is Buying That Should Be on Your List Too (Motley Fool)
Oct-21-23 05:00AM	Cathie Wood Is Buying These Top Growth Stocks -- and Both Could Make You Richer Over Time (Motley Fool)
Oct-19-23 11:46AM	Intellia's (NTLA) IND for Gene-Editing Therapy Gets FDA Clearance (Zacks)
Oct-18-23 04:10PM	Intellia Stumbles As It Aims For A First-Ever In CRISPR Gene Editing (Investor's Business Daily)
07:00AM	Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application to Initiate a Pivotal Phase 3 Trial of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy (GlobeNewswire)
Oct-16-23 12:39PM	Intellia's (NTLA) HAE Candidate Gets EMA's PRIME Designation (Zacks)
10:43AM	16 Best Stocks to Buy and Hold for the Next 15 Years According to Cathie Woods Portfolio (Insider Monkey)
Oct-14-23 12:20PM	2 Growth Stocks That Could Deliver Parabolic Returns in Under 5 Years (Motley Fool)
Oct-13-23 08:38AM	Intellia Therapeutics Receives Priority Medicines (PRIME) Designation From the European Medicines Agency for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema (GlobeNewswire)
Oct-12-23 08:57AM	2 Brilliant Growth Stocks to Buy and Hold Forever (Motley Fool)
Oct-10-23 02:00PM	Down 45%, Is Intellia a Buy? (Motley Fool)
10:07AM	This Cathie Wood Stock Is Poised to Double, Says Wall Street (Motley Fool)
Oct-06-23 04:59AM	The Zacks Analyst Blog Highlights Novavax, ALX Oncology, Regeneron Pharmaceuticals, Intellia and Moderna (Zacks)
Oct-05-23 09:15AM	This Market-Beating Stock Just Gave Investors More Reasons to Invest (Motley Fool) +5.43%
Oct-04-23 09:27AM	Intellia (NTLA), Regeneron Expand Deal for Gene-Editing Therapies (Zacks)
Oct-03-23 10:07AM	Intellia Therapeutics Could Rise 167%, Per Wall Street, But Is It a Buy? (Motley Fool)
07:58AM	UPDATE 1-Regeneron, Intellia to make gene editing therapies in expanded collaboration (Reuters)
07:08AM	Regeneron, Intellia Therapeutics expand research collaboration to make gene editing therapies (Reuters)
07:00AM	Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases (GlobeNewswire)

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BASTA JAMES	EVP, General Counsel	Mar 04 '24	Sale	32.99	2,297	75,778	81,571	Mar 05 04:10 PM
Clark Eliana	EVP, Chief Technical Officer	Mar 04 '24	Sale	32.99	605	19,959	71,470	Mar 05 04:10 PM
Sepp-Lorenzino Laura	EVP, Chief Scientific Officer	Jan 08 '24	Sale	28.87	2,275	65,682	43,927	Jan 10 04:15 PM
LEONARD JOHN M	President and CEO	Jan 03 '24	Sale	29.46	19,223	566,310	846,486	Jan 05 04:51 PM
Lebwohl David	EVP, Chief Medical Officer	Jan 03 '24	Sale	29.46	5,843	172,135	54,372	Jan 05 04:50 PM
Sepp-Lorenzino Laura	EVP, Chief Scientific Officer	Jan 03 '24	Sale	29.46	5,532	162,973	46,202	Jan 05 04:50 PM
Goddard Glenn	EVP, Chief Financial Officer	Jan 03 '24	Sale	29.46	5,365	158,053	40,585	Jan 05 04:49 PM
Clark Eliana	EVP, Chief Technical Officer	Jan 03 '24	Sale	29.50	4,608	135,954	40,845	Jan 05 04:44 PM
Hicks Derek	EVP, Chief Business Officer	Jan 03 '24	Sale	29.46	3,877	114,216	36,987	Jan 05 04:46 PM
BASTA JAMES	EVP, General Counsel	Jan 03 '24	Sale	29.46	3,805	112,095	51,474	Jan 05 04:45 PM
Bhanji Muna	Director	Oct 31 '23	Sale	23.90	265	6,334	11,996	Nov 02 04:42 PM
Bhanji Muna	Director	Jul 31 '23	Sale	42.33	265	11,217	12,261	Aug 02 05:19 PM
Bhanji Muna	Director	Jul 06 '23	Sale	39.30	1,867	73,373	12,526	Jul 10 05:21 PM
Clark Eliana	EVP, Chief Technical Officer	Jul 03 '23	Sale	40.51	360	14,584	45,146	Jul 06 03:34 PM
Clark Eliana	EVP, Chief Technical Officer	Jun 20 '23	Option Exercise	12.27	5,000	61,350	50,146	Jun 22 05:52 PM
Clark Eliana	EVP, Chief Technical Officer	Jun 20 '23	Sale	45.00	5,000	225,000	45,146	Jun 22 05:52 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

KRRO

Korro Bio Inc.

NTLA

Intellia Therapeutics Inc

Upgrade your FINVIZ experience